Therapeutic Asset Ratings

160 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Karxt Bipolar Disorder Type I With Mania	Bristol-Myers Squibb	P3	B (60)
Nivolumab Extensive-Stage Small Cell Lung Cancer	Bristol-Myers Squibb	P3	B (60)
TROSPIUM Mania	Bristol-Myers Squibb	P3	B (60)
Xanomeline Mania	Bristol-Myers Squibb	P3	B (60)
Orm-6151 Limited Stage Small Cell Lung Cancer	Bristol-Myers Squibb	P2	B (60)
Admilparant Idiopathic Pulmonary Fibrosis	Bristol-Myers Squibb	P3	B (59)
Tas-102 Colorectal Neoplasms	Bristol-Myers Squibb	P3	B (59)
Relatlimab Hepatocellular Carcinoma	Bristol-Myers Squibb	P2	B (59)
Adagrasib Advanced Cancer	Bristol-Myers Squibb	P2	B (58)
Palbociclib Advanced Solid Tumors	Bristol-Myers Squibb	P2	B (58)
Karx-Ec Psychosis	Bristol-Myers Squibb	P3	B (57)
Karxt Psychosis	Bristol-Myers Squibb	P3	B (57)
ERIBULIN/FARLETUZUMAB ANTIBODY DRUG CONJUGATE Neoplasms, Ovarian	Bristol-Myers Squibb	P2	B (57)
LISPRO-PH20 COMPONENT RHUPH20 Melanoma	Bristol-Myers Squibb	P3	B (56)
Epirubicin Pancreatic Ductal Adenocarcinoma	Bristol-Myers Squibb	P2	B (56)
Palbociclib Ovarian Cancer	Bristol-Myers Squibb	P2	B (56)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Advanced Solid Tumors	Bristol-Myers Squibb	P1/2	CCC (55)
LISPRO-PH20 COMPONENT RHUPH20 Clear Cell Renal Cell Carcinoma	Bristol-Myers Squibb	P3	CCC (54)
Relatlimab Colorectal Neoplasms	Bristol-Myers Squibb	P3	CCC (54)
Repotrectinib Carcinoma, Non-Small-Cell Lung	Bristol-Myers Squibb	P3	CCC (54)
TROSPIUM Bipolar Disorder	Bristol-Myers Squibb	P3	CCC (54)
Xanomeline Bipolar Disorder	Bristol-Myers Squibb	P3	CCC (54)
BMS-986504 Carcinoma, Non-Small-Cell Lung	Bristol-Myers Squibb	P2/3	CCC (54)
BMS-986446 Alzheimer Disease, Early Onset	Bristol-Myers Squibb	P2	CCC (53)
Karx-Ec Alzheimer Disease	Bristol-Myers Squibb	P3	CCC (52)

Showing 26 to 50 of 160 assets

PreviousPage 2 of 7Next